Antisense oligonucleotide mediated therapy of spinal muscular atrophy
about
Molecular Mechanisms of Neurodegeneration in Spinal Muscular AtrophyNucleic acid aptamers: research tools in disease diagnostics and therapeuticsA short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophyGEMINs: potential therapeutic targets for spinal muscular atrophy?ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy.Targeting SR proteins improves SMN expression in spinal muscular atrophy cells.Advances in therapeutic development for spinal muscular atrophy.Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.Mechanistic principles of antisense targets for the treatment of spinal muscular atrophyChronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy.An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophySpinal muscular atrophy: an update on therapeutic progressMegalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes.Diverse role of survival motor neuron protein.A Multilayered Control of the Human Survival Motor Neuron Gene Expression by Alu Elements.Gender-Specific Amelioration of SMA Phenotype upon Disruption of a Deep Intronic Structure by an Oligonucleotide.Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.
P2860
Q26752798-ADC35AA0-0B6B-4058-9604-70F59BF219F6Q26824321-FA3090D8-C69B-4A20-B652-78E4514E48C9Q34001036-47AAE61D-D99D-4A6E-93E2-A4654FE14703Q34342044-BEFDF2D5-A1E0-41A4-BD58-7E59C389698CQ34555103-570A09BC-C39D-472C-993A-DCA7849D7127Q34704344-7614815A-002D-4D06-BEA2-2F68CE31E65EQ35167319-7257D552-59C3-40BE-898A-79E75DBEB7BEQ36297097-4F44C381-F732-427E-8D0C-46DFCD928643Q36322222-27B1C068-0A29-4505-A11F-2D2A682C1D95Q36484406-21B47CFB-4514-47E7-A7C9-71BFB16A9862Q37197829-7BAD9DB3-7FD0-4E7D-BB08-D55FF3B02B5DQ37302832-09E69A19-0AD8-44B3-A2F6-E4E861605A5CQ38791524-C06EB7AF-0A26-4A7D-8F2C-B35FDF456ED5Q39092025-672D50BC-0ABE-442F-96E8-F44E78A33671Q47157625-77B1D177-5BA8-4BBF-A053-74B2C8BA210CQ48613900-A3EB27B4-92FC-4521-9BF7-E05D95C2B042Q55365906-AD53568D-C172-4682-A935-9C40A80F644A
P2860
Antisense oligonucleotide mediated therapy of spinal muscular atrophy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antisense oligonucleotide mediated therapy of spinal muscular atrophy
@en
Antisense oligonucleotide mediated therapy of spinal muscular atrophy.
@nl
type
label
Antisense oligonucleotide mediated therapy of spinal muscular atrophy
@en
Antisense oligonucleotide mediated therapy of spinal muscular atrophy.
@nl
prefLabel
Antisense oligonucleotide mediated therapy of spinal muscular atrophy
@en
Antisense oligonucleotide mediated therapy of spinal muscular atrophy.
@nl
P2860
P50
P1476
Antisense oligonucleotide mediated therapy of spinal muscular atrophy
@en
P2093
Christine J Didonato
P2860
P2888
P356
10.2478/S13380-013-0109-2
P577
2013-03-01T00:00:00Z
P5875
P6179
1027187561